Alzamend Neuro Q1 EPS $(0.68) Misses $(0.56) Estimate, Sales $0.00, Same YoY

Benzinga Newsdesk www.benzinga.com Negative 90.6%

Neg 90.6% Neu 0% Pos 0%

Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.56) by 21.43 percent. This is a 46.88 percent increase over losses of $(1.28) per share from the same period last year. The company reported $0.00 in sales this quarter. This is the same as the same period last year.